MEP33008A - Derivati biciklističkih imino kisjelina kao inhibitori matriksmetaloproteinaze - Google Patents
Derivati biciklističkih imino kisjelina kao inhibitori matriksmetaloproteinazeInfo
- Publication number
- MEP33008A MEP33008A MEP-330/08A MEP33008A MEP33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A
- Authority
- ME
- Montenegro
- Prior art keywords
- diseases
- joint
- matrixmetalloproteinases
- inhibitors
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (de) | 2003-09-27 | 2003-09-27 | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
| PCT/EP2004/010248 WO2005030728A1 (de) | 2003-09-27 | 2004-09-14 | Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP33008A true MEP33008A (hr) | 2010-10-10 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-330/08A MEP33008A (hr) | 2003-09-27 | 2004-09-14 | Derivati biciklističkih imino kisjelina kao inhibitori matriksmetaloproteinaze |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (hr) |
| JP (1) | JP4861179B2 (hr) |
| KR (1) | KR20060086367A (hr) |
| CN (1) | CN1856478B (hr) |
| AR (1) | AR046165A1 (hr) |
| AT (1) | ATE550327T1 (hr) |
| AU (1) | AU2004275937A1 (hr) |
| BR (1) | BRPI0414594A (hr) |
| CA (1) | CA2539731A1 (hr) |
| DE (1) | DE10344936A1 (hr) |
| IL (1) | IL174040A0 (hr) |
| MA (1) | MA28075A1 (hr) |
| ME (1) | MEP33008A (hr) |
| MX (1) | MXPA06002927A (hr) |
| MY (1) | MY139830A (hr) |
| NO (1) | NO20061837L (hr) |
| NZ (1) | NZ546158A (hr) |
| PE (1) | PE20050432A1 (hr) |
| RS (1) | RS20060194A (hr) |
| RU (1) | RU2335494C2 (hr) |
| TW (1) | TW200520755A (hr) |
| UY (1) | UY28539A1 (hr) |
| WO (1) | WO2005030728A1 (hr) |
| ZA (1) | ZA200601501B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE102005002500A1 (de) | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CA2695504C (en) | 2007-08-03 | 2017-05-30 | Nucitec S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (hr) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (fr) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| DK0861236T4 (da) | 1995-11-13 | 2006-12-18 | Sanofi Aventis Deutschland | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer |
| SK25699A3 (en) * | 1996-08-28 | 1999-10-08 | Procter & Gamble | 1,4-heterocyclic metallprotease inhibitors |
| JP3563411B2 (ja) * | 1997-01-23 | 2004-09-08 | エフ・ホフマン−ラ ロシュ アーゲー | スルファミド−メタロプロテアーゼ阻害剤 |
| DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/de not_active Withdrawn
-
2004
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/pt not_active IP Right Cessation
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/zh not_active Expired - Fee Related
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/sr unknown
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/ja not_active Expired - Fee Related
- 2004-09-14 EP EP04786944A patent/EP1670766B1/de active Active
- 2004-09-14 AT AT04786944T patent/ATE550327T1/de active
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/ru not_active IP Right Cessation
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/hr unknown
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/de active Application Filing
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/ko not_active Application Discontinuation
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/es active IP Right Grant
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/es not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/zh unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/es not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/es unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/fr unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR046165A1 (es) | 2005-11-30 |
| JP4861179B2 (ja) | 2012-01-25 |
| NO20061837L (no) | 2006-06-01 |
| CN1856478B (zh) | 2010-05-26 |
| IL174040A0 (en) | 2006-08-01 |
| EP1670766A1 (de) | 2006-06-21 |
| PE20050432A1 (es) | 2005-07-21 |
| WO2005030728A1 (de) | 2005-04-07 |
| RU2006114352A (ru) | 2006-08-27 |
| MA28075A1 (fr) | 2006-08-01 |
| CA2539731A1 (en) | 2005-04-07 |
| UY28539A1 (es) | 2005-04-29 |
| JP2007506690A (ja) | 2007-03-22 |
| TW200520755A (en) | 2005-07-01 |
| BRPI0414594A (pt) | 2006-11-07 |
| ZA200601501B (en) | 2007-04-25 |
| AU2004275937A1 (en) | 2005-04-07 |
| KR20060086367A (ko) | 2006-07-31 |
| RS20060194A (en) | 2008-08-07 |
| NZ546158A (en) | 2008-11-28 |
| EP1670766B1 (de) | 2012-03-21 |
| DE10344936A1 (de) | 2005-04-21 |
| MXPA06002927A (es) | 2006-06-14 |
| MY139830A (en) | 2009-10-30 |
| CN1856478A (zh) | 2006-11-01 |
| RU2335494C2 (ru) | 2008-10-10 |
| ATE550327T1 (de) | 2012-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050532A2 (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
| HRP20050531B1 (hr) | Novi aromatski derivati fluorglikozida, lijek koji sadrži te spojeve i njihova upotreba | |
| ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
| EA201290389A8 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| AR002267A1 (es) | Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion. | |
| MA33909B1 (fr) | Pyrrolidinones accoles en tant d'inhibiteurs de syk | |
| MY147449A (en) | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
| ES2192192T3 (es) | Dieteres de catecol como inhibidores selectivos de pde iv. | |
| BRPI0607583A2 (pt) | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos | |
| EA200400595A1 (ru) | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| IS8175A (is) | Píperasín afleiður og aðferðir við notkun þeirra | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| ITMI20031311A1 (it) | Formulazioni per il trattamento di disturbi artrosici. | |
| EA200700902A1 (ru) | 3-ариламинопиридиновые производные | |
| BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| BRPI0709581A8 (pt) | compostos de bicicloeteroarila como moduladores de px27 e seu uso | |
| MX2010009658A (es) | Derivados de azetidina. | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
| BR0306643A (pt) | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical | |
| TN2019000143A1 (en) | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |